Claims for Patent: 9,446,059

Summary for Patent: 9,446,059

Title:	Carbidopa and L-dopa prodrugs and methods of use
Abstract:	The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
Inventor(s):	Benoit CARDINAL-DAVID, Vincent S. Chan, Kassibla E. DEMPAH, Brian P. ENRIGHT, Rodger F. Henry, Raimundo HO, Ye Huang, Alexander D. HUTERS, Russell C. Klix, Scott W. KRABBE, Philip R. Kym, Yanbin Lao, Xiaochun Lou, Sean E. Mackey, Mark A. Matulenko, Peter T. Mayer, Christopher P. Miller, James Stambuli, Eric A. Voight, Zhi Wang, Geoff G. Zhang, Valentino J. Stella
Assignee:	AbbVie Inc
Application Number:	US14/919,418
Patent Claims:	1. A pharmaceutical combination comprising a first compound corresponding in structure to Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2; R5 is a C1-C4-alkyl; R6 is hydrogen or a C1-C4-alkyl; and provided that at least one of R1 and R2 is —P(O)(OH)2 or —R5—O—P(O)(OH)2; and a second compound corresponding in structure Formula (II): or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2; R5 is a C1-C4-alkyl; R6 is hydrogen or a C1-C4-alkyl; and provided that at least one of R3 and R4 is —P(O)(OH)2 or —R5—O—P(O)(OH)2. 2. The pharmaceutical combination of claim 1, wherein the first compound is selected from the group consisting of and the second compound is selected from the group consisting of 3. The pharmaceutical combination of claim 1, wherein the first compound is and the second compound is 4. The pharmaceutical combination of claim 1, wherein the first compound is and the second compound is 5. The pharmaceutical combination of claim 1, wherein the first compound is and the second compound is 6. The pharmaceutical combination of claim 1, wherein the first compound is and the second compound is 7. The pharmaceutical combination of claim 1, wherein a weight ratio of the first compound or pharmaceutically acceptable salt thereof to the second compound or pharmaceutically acceptable salt thereof is from about 1:4 to about 1:10. 8. The pharmaceutical combination of claim 1, wherein the combination is an aqueous combination suitable for intragastric, subcutaneous, intramuscular, intrajejunum, oral, intranasal or intravenous administration. 9. The pharmaceutical combination of claim 1, wherein the combination is an aqueous combination suitable for subcutaneous administration. 10. A compound corresponding in structure to Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2; R5 is a C1-C4-alkyl; R6 is hydrogen or a C1-C4-alkyl; and provided that at least one of R1 and R2 is —P(O)(OH)2 or —R5—O—P(O)(OH)2. 11. The compound or pharmaceutically acceptable salt of claim 10, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, —P(O)(OH)2, and —R5—O—P(O)(OH)2; R5 is a C1-C2-alkyl; R6 is hydrogen; and provided that at least one of R1 and R2 is —P(O)(OH)2 or —R5—O—P(O)(OH)2. 12. The compound or pharmaceutically acceptable salt of claim 10, wherein R1 and R2 are each independently hydrogen or —P(O)(OH)2; R6 is hydrogen; and one of R1 and R2 is —P(O)(OH)2. 13. The compound or pharmaceutically acceptable salt of claim 10, wherein R1 and R2 are each independently hydrogen or —R5—O—P(O)(OH)2; R5 is a C1-C2-alkyl; R6 is hydrogen; and provided that one of R1 and R2 is —R5—O—P(O)(OH)2. 14. The compound or pharmaceutically acceptable salt of claim 10, wherein R1 and R2 are each independently hydrogen, —P(O)(OH)2 or —R5—O—P(O)(OH)2; R5 is a C1-C2-alkyl; R6 is a C1-C2-alkyl; and provided that one of R1 and R2 is —P(O)(OH)2 or —R5—O—P(O)(OH)2. 15. A compound corresponding in structure to Formula (II): or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are each independently hydrogen or —R5—O—P(O)(OH)2; R5 is a C1-C2-alkyl; R6 is hydrogen; and provided that one of R3 and R4 is —R5—O—P(O)(OH)2. 16. A method of treating Parkinson's disease comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical combination according to claim 1. 17. The method of claim 16, wherein the first compound is selected from the group consisting of and the second compound is selected from the group consisting of 18. The method of claim 16, further comprising administering another anti-Parkinson's agent to the subject. 19. The method of claim 16, wherein the pharmaceutical combination is an aqueous combination. 20. The method of claim 19, wherein the aqueous pharmaceutical combination is administered by intragastric, subcutaneous, intramuscular, intranasal, intrajejunum, oral or intravenous administration. 21. The method of claim 20, wherein the aqueous pharmaceutical combination is administered by subcutaneous administration. 22. The method of claim 21, wherein the method comprises substantially continuous administration of the pharmaceutical combination over a period of at least about 12 hours. 23. A kit comprising the pharmaceutical combination of claim 1. 24. A compound selected from the group consisting of